Triple Helix Discovery Engine
"Triple Helix" Innovation Model
1. Triple Helix _ Sectors
4. Intermediaries ... Investors, Lenders, NonProfits, Specialists (Legal, IP, Marketing, Consultants, SMEs, Etc.)
5. Intermediary (Investors, Funders, Regulator) Rankings, Ratings & Reviews
Intermediaries: Geographic Info
*Bioscience Regional Clusters & HotSpots
*Industry: Massachusetts
Stoke Therapeutics, Inc. (NASDAQ: STOK)*

Organization & Developments: Stoke Therapeutics

Parents

*Antisense is a gene silencing technique where the translation process is blocked so that the mRNA or messenger RNA is not able to meet with the ribosome to create a particular amino acid, which, in the case of diseases, happens to be the wrong amino acid.
*Developing antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases
*The company’s intellectual property is based on the work of co-founder Adrian R. Krainer, Ph.D., of Cold Spring Harbor Laboratory in New York, who was also a co-inventor of SPINRAZA, the first antisense oligonucleotide, or ASO, medicines (SPINRAZA is a $2bn blockbuster
2020: Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
2021: Sizing Up Stoke Therapeutics
2022: Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet Syndrome_ seekingalpha.com
2024: Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
2025: Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
2025: Stoke Therapeutics Stock Slips as CEO Steps Down
2025: Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
2025: Stoke Therapeutics: Impressive Pipeline And Big Backers